Lord Abbett & CO. LLC Sells 108,079 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Lord Abbett & CO. LLC lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 27.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 284,159 shares of the company's stock after selling 108,079 shares during the quarter. Lord Abbett & CO. LLC owned about 0.99% of Krystal Biotech worth $51,726,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Segall Bryant & Hamill LLC lifted its position in shares of Krystal Biotech by 352.4% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company's stock worth $28,605,000 after purchasing an additional 122,407 shares during the last quarter. State Street Corp boosted its position in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company's stock valued at $264,455,000 after acquiring an additional 119,936 shares during the period. Principal Financial Group Inc. grew its stake in shares of Krystal Biotech by 1,972.0% in the second quarter. Principal Financial Group Inc. now owns 123,469 shares of the company's stock worth $22,674,000 after acquiring an additional 117,510 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company's stock worth $35,583,000 after acquiring an additional 103,928 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after acquiring an additional 62,178 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on KRYS shares. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Chardan Capital restated a "buy" rating and set a $212.00 price target on shares of Krystal Biotech in a research note on Thursday. HC Wainwright reaffirmed a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Tuesday, December 10th. William Blair raised Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Finally, Stifel Nicolaus upped their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech has a consensus rating of "Buy" and an average target price of $206.67.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded down $9.76 during midday trading on Friday, hitting $163.64. 541,626 shares of the company were exchanged, compared to its average volume of 322,730. The firm has a 50 day simple moving average of $181.27 and a 200-day simple moving average of $185.06. The firm has a market cap of $4.71 billion, a P/E ratio of 92.45 and a beta of 0.80. Krystal Biotech, Inc. has a 52 week low of $107.50 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the previous year, the company earned ($0.67) EPS. The firm's revenue for the quarter was up 879.9% compared to the same quarter last year. Equities research analysts expect that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).